Provided by Tiger Trade Technology Pte. Ltd.

Terns Pharmaceuticals, Inc.

37.77
+2.436.88%
Post-market: 37.73-0.0400-0.11%19:31 EST
Volume:1.76M
Turnover:65.49M
Market Cap:4.12B
PE:-36.60
High:38.03
Open:35.45
Low:35.45
Close:35.34
52wk High:48.26
52wk Low:1.87
Shares:109.00M
Float Shares:80.32M
Volume Ratio:0.63
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0319
EPS(LYR):-1.1175
ROE:-29.12%
ROA:-19.94%
PB:14.49
PE(LYR):-33.80

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Terns Pharmaceuticals (TERN)

TIPRANKS
·
Feb 05

A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update

Simply Wall St.
·
Feb 04

BRIEF-Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule

Reuters
·
Feb 03

What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders

Simply Wall St.
·
Feb 02

Mizuho Securities Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)

TIPRANKS
·
Jan 23

Terns Pharmaceuticals Expands Global Rights to TERN-701

TIPRANKS
·
Jan 23

Terns Pharmaceuticals Inc - Amends License Agreement With Hansoh Healthtech - SEC Filing

THOMSON REUTERS
·
Jan 23

Terns Pharmaceuticals: Obligated to Pay Hansoh One-Time Upfront License Fee $1.0 Mln & Tiered Royalties 0.75% to 1.25% on Annual Net Sales

THOMSON REUTERS
·
Jan 23

Assessing Terns Pharmaceuticals (TERN) Valuation After New TERN-701 Data And Capital Raise

Simply Wall St.
·
Jan 18

How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data

Simply Wall St.
·
Jan 16

De-Risked CML Lead Asset, Robust Trial Strategy, and $1B Cash Runway Underscore Buy Rating on Terns Pharmaceuticals

TIPRANKS
·
Jan 13

TERN-701’s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals

TIPRANKS
·
Jan 13

Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation

Reuters
·
Jan 12

Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative

Simply Wall St.
·
Jan 08

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 08

Terns Pharmaceuticals Chief Medical Officer Emil Kuriakose Reports Disposal of Common Shares

Reuters
·
Jan 07

Terns Pharmaceuticals Grants Equity Awards to New Employees Under Inducement Plan

Reuters
·
Jan 03

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
Jan 03

Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701

Simply Wall St.
·
Dec 16, 2025

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Dec 12, 2025